NIH Funding Opportunities and Notices

Weekly NIH Funding Opportunities and Notices

NIH Guide for Grants and Contracts

August 30, 2019

General Notices

• Notice of Changes to NIDCR's Clinical Terms of Award (CToA) Policy
  (NOT-DE-19-008)
  National Institute of Dental and Craniofacial Research

• Report on Reducing Administrative Burden for Researchers: Animal Care and Use in Research (NOT-OD-19-136)
  National Institutes of Health

• Sexual and Gender Minority Populations in NIH-Supported Research
  (NOT-OD-19-139)
  Office of the Director, NIH

Notice of Changes to Funding Opportunities

• Notice of Change of NIA Intent to Fund Awards for RFA-HL-18-023 "Stimulating Access to Research in Residency (StARR) (R38)"
  (NOT-AG-19-041)
  National Institute on Aging

• Notice of NIAMS Withdrawal from Participation in PAR-19-333 "SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1, R44) Clinical Trial Not Allowed"
  (NOT-AR-20-004)
  National Institute of Arthritis and Musculoskeletal and Skin Diseases

• Notice of NCCIH's Participation in PA-19-196 "Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research (Parent F31)
  (NOT-AT-19-035)
  National Center for Complementary and Integrative Health

• Notice of Clarification to Eligibility Information in PAR-19-349 "NCI Outstanding Investigator Award (R35 Clinical Trial Not Allowed)"
  (NOT-CA-19-069)
  National Cancer Institute

• Correction to RFA-CA-19-045 "Participant Engagement and Cancer Genome Sequencing (PE-CGS) (U2C Clinical Trial Optional)"
  (NOT-CA-19-070)
  National Cancer Institute

• Notice of Correction to Key Dates for PAR-19-345 " NIDA Program Project Grant Applications (P01 Clinical Trial Optional)"
  (NOT-DA-19-071)
  National Institute on Drug Abuse

• Notice to Extend the Expiration Date for PAR-18-205 "NIBIB Biomedical Technology Resource Centers (P41 Clinical Trials Optional)"
  (NOT-EB-19-019)
  National Institute of Biomedical Imaging and Bioengineering

• Notice of Expiration of RFA-HL-19-014 Stimulating T4 Implementation Research to Optimize Integration of Proven-effective Interventions for Heart, Lung, and Blood Diseases and Sleep Disorders into Practice (STIMULATE) (R01 Clinical Trial Not Allowed)
  (NOT-HL-19-718)
  National Heart, Lung, and Blood Institute

• Notice of NIMHD Withdrawal from Participation in PA-19-052, "NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
  (NOT-MD-20-002)
  National Institute on Minority Health and Health Disparities

• Notice of NIH Participation in the Ecology and Evolution of Infectious Diseases Program
  (NOT-TW-19-007)
  John E. Fogarty International Center
  National Institute of Allergy and Infectious Diseases
  National Institute of General Medical Sciences

Notices of Special Interest

• Notice of Special Interest (NOSI): Epidemiology of Drug Abuse
  (NOT-DA-19-066)
  National Institute on Drug Abuse

• Notice of Special Interest in X-ray-based Devices for Trauma Care
  (NOT-EB-19-015)
  National Institute of Biomedical Imaging and Bioengineering

• Notice of Special Interest in Ultrasound and Optics-based Devices for Trauma Care
  (NOT-EB-19-016)
  National Institute of Biomedical Imaging and Bioengineering

• Notice of Special Interest in Radiation Monitoring for Trauma Care
  (NOT-EB-19-017)
  National Institute of Biomedical Imaging and Bioengineering

• Notice of Special Interest in Physiological Monitoring and Point of Care Technologies for Trauma Care
  (NOT-EB-19-018)
  National Institute of Biomedical Imaging and Bioengineering

Funding Opportunities

• Intervening with Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health Care Utilization (R01 Clinical Trial Optional)
  (PAR-19-352)
  National Cancer Institute
  Application Receipt Date(s): October 17, 2019; then Standard dates apply. The first standard due date for this FOA is February 5, 2020.
• Neural Regulation of Cancer (R01 Clinical Trial Not Allowed)
  (PAR-19-353)
  National Cancer Institute
  Application Receipt Date(s): October 21, 2019; May 27, 2020; October 21, 2020; May 27, 2021; October 21, 2021; May 27, 2022 , by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
• Neural Regulation of Cancer (R21 Clinical Trial Not Allowed)
  (PAR-19-354)
  National Cancer Institute
  Application Receipt Date(s): October 21, 2019; May 27, 2020; October 21, 2020; May 27, 2021; October 21, 2021; May 27, 2022
• Intervening with Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health Care Utilization (R21 Clinical Trial Optional)
  (PAR-19-355)
  National Cancer Institute
  Application Receipt Date(s): Standard dates apply. The first standard due date for this FOA is October 16, 2019
• NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional) (PAR-19-356)
  National Cancer Institute
  Application Receipt Date(s): October 18, 2019; February 20, 2020, June 19, 2020; October 20, 2020; February 19, 2021; June 21, 2021; October 20, 2021; February 22, 2022; June 21, 2022
• Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R21 Clinical Trial Optional)
  (PAR-19-358)
  National Cancer Institute
  Application Receipt Date(s): Standard dates apply. The first standard due date for this FOA is October 16, 2019
• Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R03 Clinical Trial Optional)
  (PAR-19-359)
  National Cancer Institute
  Application Receipt Date(s): Standard dates apply. The first standard due date for this FOA is October 16, 2019.
• Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R01 Clinical Trial Optional)
  (PAR-19-360)
  National Cancer Institute
  Application Receipt Date(s): October 17, 2019; then Standard dates apply. The first standard due date for this FOA is February 5, 2020.
• Small-Cell Lung Cancer (SCLC) Consortium: Therapeutic Development and Mechanisms of Resistance (U01 Clinical Trial Not Allowed)
  (PAR-19-361)
  National Cancer Institute
  Application Receipt Date(s): November 12, 2019; March 11, 2020; November 12, 2020; March 11, 2021; November 12, 2021; March 11, 2022 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s) Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Food as Medicine: Food Insecurity and HIV-related Comorbidities, Coinfections, and Complications within the Mission of the NIDDK (R01 Clinical Trial Optional)
  (RFA-DK-19-019)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date(s) listed below.
• The NINDS Human Cell and Data Repository (U24 - Clinical Trial Not Allowed)
  (RFA-NS-19-038)
  National Institute of Neurological Disorders and Stroke
  Application Receipt Date(s): October 22, 2019 No late applications will be accepted for this Funding Opportunity Announcement.
• Data Coordinating and Operations Center for the ECHO IDeA States Pediatric Clinical Trials Network - 2 (U24 - Clinical Trial Required -Infrastructure)
  (RFA-OD-19-025)
  National Institutes of Health
  National Institute of Allergy and Infectious Diseases
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute of General Medical Sciences
  National Institute of Neurological Disorders and Stroke
  Office of Behavioral and Social Science Research
  Application Receipt Date(s): December 2, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Clinical Sites for the ECHO IDeA States Pediatric Clinical Trials Network - 2 (UG1 Clinical Trial Required)
  (RFA-OD-19-026)
  National Institutes of Health
  National Institute of Allergy and Infectious Diseases
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute of General Medical Sciences
  National Institute of Neurological Disorders and Stroke
  Office of Behavioral and Social Science Research
  Application Receipt Date(s): December 2, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
• Multisite Clinical Center Common Fund Acute to Chronic Pain Signatures Program: Acute Peri-operative Pain or Musculoskeletal Trauma (UM1 Clinical Trial Optional)
  (RFA-RM-19-013)
  Office of Strategic Coordination (Common Fund)
  Application Receipt Date(s): November 26, 2019